Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 744,000	$ 655,000
Accounts receivable	259,000	355,000
Inventories, net of allowance	33,000	16,000
Prepaid expenses and other current assets	44,000	39,000
Total current assets	1,080,000	1,065,000
In-process research and development (Note 8)	1,893,000	1,893,000
Property and equipment, net of depreciation	63,000	95,000
Other non-current assets	35,000	35,000
Right-of-use, operating lease, net of amortization	386,000	411,000
Deferred offering cost		122,000
Investment in South Korean joint venture	99,000
Total assets	3,556,000	3,621,000
Current liabilities:
Accounts payable and accrued expenses	812,000	602,000
Note payable	50,000	50,000
Line of credit	50,000	50,000
Convertible notes payable	3,523,000	3,957,000
Discount on convertible notes payable, and line of credit, net of amortization	(834,000)	(1,472,000)
Lease liability	114,000	125,000
Deferred revenue	9,000	35,000
Total current liabilities	4,731,000	4,354,000
Long-term liabilities:
Long-term debt	700,000	700,000
Discount on convertible notes payable, net of amortization	(153,000)	(182,000)
Lease liability	271,000	286,000
Total liabilities	6,192,000	5,801,000
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Preferred Series A, $.00067 Par Value, 50,000,000 shares authorized, -0- shares issued and outstanding, at December 31, 2019 and March 31, 2020, respectively.
Common stock, $.00067 Par Value, 400,000,000 shares authorized, 166,256,024 and 178,479,317 shares issued, at December 31, 2019 and March 31, 2020.	119,000	111,000
Additional paid-in capital	123,121,000	121,327,000
Accumulated other comprehensive loss	(99,000)	(99,000)
Accumulated deficit	(125,866,000)	(123,492,000)
Total BioLargo, Inc. and subsidiaries stockholders’ deficit	(2,725,000)	(2,153,000)
Non-controlling interest (Note 8)	89,000	(27,000)
Total stockholders’ deficit	(2,636,000)	(2,180,000)
Total liabilities and stockholders’ equity (deficit)	3,556,000	3,621,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 8)	643,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Current liabilities:
Note payable	1,007,000	1,007,000
Convertible Notes and Notes Payable [Member]
Long-term liabilities:
Long-term debt	$ 700,000	$ 700,000